Core Viewpoint - OSE Immunotherapeutics announced that its partner Boehringer Ingelheim will present early clinical data on SIRPα blockade at the ASCO 2025 Annual Meeting, highlighting the potential of their monoclonal antibodies in cancer therapy [2][5]. Company Overview - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation, aiming to address unmet patient needs [10]. - The company collaborates with leading academic institutions and biopharmaceutical companies to bring transformative medicines to market [10]. Clinical Trials and Results - In a Phase 1b study, Boehringer's SIRPα monoclonal antibody, BI 765063, showed a manageable safety profile and preliminary signs of immune activation and anti-tumor activity when combined with PD-1 inhibitor ezabenlimab and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma [3][8]. - Another open-label Phase I trial demonstrated that the next-generation SIRPα monoclonal antibody, BI 770371, was well tolerated both alone and in combination with ezabenlimab in patients with advanced solid tumors, with no dose-limiting toxicities reported [4][8]. Future Development - Boehringer Ingelheim will advance the next-generation SIRPα inhibitor BI 770371 into a Phase 1b study, indicating ongoing commitment to developing innovative cancer therapies [6][8]. - The dual activation strategy of SIRPα blockade paired with PD-1 inhibition is viewed as a promising approach to enhance anti-tumor responses [5]. Presentation Details - The presentations at ASCO 2025 will include: - Title: An Open-Label, Phase Ib Trial of the SIRPα Inhibitor BI 765063 in Combination with the PD-1 Inhibitor Ezabenlimab and Cetuximab in Patients with HNSCC [7] - Title: An Open-label, Phase I Trial of the SIRPα Monoclonal Antibody, BI 770371, Alone and in Combination with the PD-1 Inhibitor Ezabenlimab in Patients with Advanced Solid Tumors [7].